Phage therapy: The precise biological approach against multidrug-resistant pathogens
Modern medicine is facing an invisible abyss. While we focus on technological breakthroughs in AI and surgery, we are losing ground at the microscopic level. This is the global resistance crisis. Bacteria that were once defeated by a simple course of penicillin are evolving into “superbugs” against which no conventional medicine works anymore. In this context, bacteriophage therapy is returning to the scientific spotlight as one of the most promising solutions to antibiotic resistance.
Summary: Key takeaways
-
Precision medicine: Phages selectively eliminate only the disease-causing bacteria while sparing the beneficial microbiome.
-
PAS effect: Phage–antibiotic synergy makes it possible to make resistant germs susceptible to medicines again.
-
Evolutionary trap: Bacteria can hardly defend themselves against phages and antibiotics at the same time without losing fitness.
-
Historical head start: Eastern Europe (especially Georgia) has been using phages successfully in clinical practice for a century.
-
Individualised therapy: Each treatment is tailored precisely to the patient’s bacterial strain using a phagogram.
1. The dead end of conventional antibiotics
Since the discovery of penicillin in 1928, we have relied on chemical warfare against bacteria. Antibiotics usually work by destroying the bacterial cell wall, inhibiting protein synthesis, or disrupting DNA replication.
The problem of broad-spectrum activity
Conventional antibiotics are often “broad-spectrum weapons”. They not only kill the pathogen causing pneumonia, but also decimate the beneficial bacteria in our gut. This leads to dysbiosis, weakens the immune system, and paradoxically creates room for new, resistant germs.
The emergence of superbugs
Bacteria multiply rapidly and exchange genetic material with one another (horizontal gene transfer). Through the massive use of antibiotics in human medicine and animal husbandry, we have created enormous selective pressure. The result is pathogens from the so-called ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter) that are immune to almost all last-resort antibiotics.
2. Bacteriophages: The biology of natural adversaries
Bacteriophages (phages for short) are viruses whose sole purpose in life is to infect and destroy bacteria. They are the most abundant biological entities on Earth—one millilitre of seawater can contain up to 100 million phages.
How phages work
A phage is highly specialised. It recognises its target bacterium via specific surface structures (receptors). After “docking”, it injects its genetic material into the cell.
Inside, the phage takes control and forces the bacterium to produce hundreds of new phages. At the end of this lytic cycle, the bacterium bursts (lysis) and releases the new phages, which immediately attack neighbouring bacteria of the same strain.
3. The scientific sensation: Phage–antibiotic synergy (PAS)
One of the most exciting areas of research today is not replacing antibiotics with phages, but combining them. This effect is known as phage–antibiotic synergy (PAS).
The mechanism in detail
Scientific studies show that, under the combined assault of phages and antibiotics, bacteria end up in an evolutionary dead end.
-
Cell enlargement: Certain antibiotics (e.g. beta-lactams) at sublethal doses cause bacteria to stop dividing and instead grow filamentously (elongated). This larger surface area provides more space for phage receptors and leads to a massively increased phage yield per bacterial cell.
-
Trade-off effect: Bacteria often use the same pump mechanisms (efflux pumps) to expel antibiotics that phages use as entry points. If the bacterium wants to become resistant to the phage, it must modify or close this pump—thereby losing its resistance to the antibiotic.
-
Biofilm degradation: Many chronic infections are protected by biofilms (slimy layers) that are impenetrable to antibiotics. Phages produce enzymes (depolymerases) that chemically dissolve this biofilm and clear the way for the antibiotic.
Background information: You can find more on the mechanisms of synergy in our in-depth article on the study on phages and antibiotics.
4. Excursus: The Georgian legacy—why the East is ahead of us
While the West abandoned phage therapy after the Second World War in favour of the more profitable antibiotic industry, it remained the gold standard in the Soviet Union, especially in Georgia.
The Eliava Institute in Tbilisi is now the global point of contact for desperate patients. There, phage cocktails are not “invented” in the laboratory, but isolated from the environment (wastewater, rivers) and continuously adapted to the currently circulating bacterial strains. In Georgia, you can simply buy phage preparations for gastrointestinal infections or purulent inflammations at the pharmacy. Only now is the West beginning to translate this decades of clinical experience into controlled studies.
5. Personalised therapy: The phagogram
A key difference from conventional medicine is the degree of personalisation. You cannot take “a phage for pneumonia”. You need the phage that matches exactly the specific bacterial strain that has infected the patient.
To do this, a phagogram is created. In the laboratory, bacterial samples from the patient are brought together with various phages from a database (biobank). Only if the phages dissolve the bacteria on the Petri dish (forming holes in the bacterial lawn) is the therapy promising. This precision makes bacteriophage therapy a genuine form of personalised medicine.
6. Use in chronic conditions: More than acute medicine
Phage therapy shows its greatest strengths where antibiotics chronically fail:
-
Diabetic foot syndrome: Chronic wounds that often lead to amputation can be saved through local phage application.
-
Cystic fibrosis: Patients suffer from persistent colonisation of the lungs with Pseudomonas. Phages can reduce the bacterial load and stabilise lung function.
-
Prosthetic joint infections: Bacteria on artificial joints form extremely dense biofilms. The PAS strategy is often the only alternative to surgical removal of the joint.
7. Regulatory hurdles and the way forward
Why are phages not yet available in every German GP practice? The problem lies in medicines law. Because phages are biologically active and replicate (and change), they do not fit into the rigid approval framework for chemical substances. In Germany, their use is usually only possible as an “individual therapeutic trial” (under the Declaration of Helsinki).
Nevertheless, there is movement: centres such as the Charité in Berlin or the military hospital in Brussels are pioneering work to make phages legally safe to use as “magistral preparations” (individually compounded pharmacy preparations).
FAQ – Frequently asked questions
1. Are phages dangerous for humans? No. Phages are highly specialised for bacteria. They cannot infect human cells because they lack the appropriate receptors. They are as harmless to us as water.
2. Can I simply replace antibiotics with phages? In many cases, the goal is not replacement, but supplementation. Phage–antibiotic synergy shows that the combination often works most safely and quickly. Stopping antibiotics on your own initiative is not advisable.
3. Where can I undergo phage therapy? Information on current clinics and the legal framework can be found on our overview page on treatments. The route often leads via specialised laboratories in Poland or Georgia.
4. How are phages administered? Depending on the site of infection: as an oral solution (gastrointestinal), as an aerosol (lungs), topically as a gel (wounds) or—in rare, controlled cases—intravenously.
5. How long does a treatment take? This varies greatly from person to person. For acute infections, days may be sufficient; for decades-long chronic bone infections, a course can take several weeks or months.
Conclusion: A biological alliance for the future
Bacteriophage therapy is not “hype”, but a return to proven biological logic. In a world where chemical weapons (antibiotics) are becoming blunt, we must learn to work with the natural enemies of our enemies. Phage–antibiotic synergy offers us the chance to end the era of powerlessness against multidrug-resistant germs.
It is time for research, policymakers, and the healthcare system to set the course so that this form of therapy does not remain a privilege for patients who make the journey to Georgia, but becomes an integral part of our healthcare provision.
Further resources:
Disclaimer: This article is for scientific information and does not constitute medical advice. If you have an infection, always consult a specialist physician.
Author: Elena Kastner
Elena Kastner is an experienced specialist journalist focusing on health communication. Her focus is on evidence-based reporting and quality assurance of medical information in the digital space. With her expertise, she bridges the gap between scientific depth and practical applicability.
